SALT LAKE CITY, March 01, 2024 Recursion , a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor.
2023 net revenues increased 4.5% to $1.05 billion, compared to 20222023 net income of $51 million or $0.18 per diluted share2023 Adjusted EBITDA increased 4.3% to $528 million2023 Adjusted EPS .
908 Devices Inc. , a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today announced it will participate in the following investor conferences.
Cowen.
Schrödinger , whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in the following.